Overview

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

Evaluation of use of ranolazine in patients with stable heart pain with cardiac magnetic resonance imaging (CMRI) and phosphorous-31 magnetic resonance spectroscopy (31P MRS). Subsequent testing using these modalities will show improved oxygen to the heart muscle.

Details

Lead Sponsor:

Westside Medical Associates of Los Angeles

Collaborator:

Gilead Sciences

Treatments:

Ranolazine